What is Generate Biomedicines, Inc. 's price / book?

Generate Biomedicines, Inc. (GENB) reported price / book of 3.1× in Q1 2026.

What does price / book mean?

Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Generate Biomedicines, Inc. GENB Price / book

Price / book at other companies

Piper SandlerPIPR

4.1×+0.4×

NNN REITNNN

1.8×0.0×

RepligenRGEN

3.2×-0.4×

SSR MiningSSRM

1.7×+1.0×

MYR GroupMYRG

5.1×+1.1×

WEXWEX

4.1×-3.4×

Other financials

Income statement

See full

Revenue$7.2M-18.1%

Operating income-$64.1M-33.1%

Net income-$61.4M-47.4%

EPS (diluted)-$1.07+34.0%

Balance sheet

See full

Cash & equivalents$160.6M-27.2%

Total debt$65.6M—

Total equity$514.8M+209%

Total assets$625.7M—

Cash flow

See full

Operating cash flow-$80.4M-51.2%

CapEx$3.8M+403%

Free cash flow-$84.2M-56.1%

Valuation

See full

Market cap$1.86B—

Enterprise value$1.76B—

Returns & leverage

See full

Debt / equity0.1×—

Current ratio9.2×—

Where this comes from

Calculated from Generate Biomedicines, Inc. ’s reported figures.

market cap/total stockholders equity=3.1×

Based on the most recent quarter.

The official record: Generate Biomedicines, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Generate Biomedicines, Inc. 's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Generate Biomedicines, Inc. 's price / book?: Generate Biomedicines, Inc. (GENB) reported price / book of 3.1× in Q1 2026.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.